Company intelligence / Profile preview
Metcela Inc.
Kawasaki, Kanagawa, Japanmetcela.com ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Phase 3
01
Overview
Metcela has initiated a Phase I clinical trial of its autologous fibroblast-based therapy MTC001 for chronic ischemic heart failure. JRM‑001, targeting single ventricle congenital defects, has received regulatory designations supporting its development as an orphan regenerative medicine product.
- Therapeutic areas
- Cardiovascular
- Modalities
- Autologous cell therapy (patient-derived cells)Stem cell-based therapyFibroblast-based therapy (VCAM-1-positive Cardiac Fibroblasts)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Japan Lifeline Co., Ltd.AMED CiCLE grant programUniversity of Tsukuba joint research since April 2017
Beyond the preview
Go deeper on Metcela Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Metcela Inc..